Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1

Digestive Diseases and Sciences

Volumn 61, Issue 11, 2016, Pages 3190-3198

  Cabrera, Daniel ^a,b,c   Ruiz, Alex ^d   Cabello Verrugio, Claudio ^e,f   Brandan, Enrique ^c   Estrada, Lisbell ^b   Pizarro, Margarita ^a   Solis, Nancy ^a   Torres, Javiera ^g   Barrera, Francisco ^a   Arrese, Marco ^a,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD BERNARDO O'HIGGINS   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^e UNIVERSIDAD ANDRÉS BELLO   (Chile)

^f Pontificia Universidad Católica de Chile   (Chile)

^g PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Fructose; Insulin; Muscular atrophy; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Sarcopenia

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MYOSIN HEAVY CHAIN; SOMATOMEDIN C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; INSULIN-LIKE GROWTH FACTOR-1, MOUSE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; HEPATIC AVAILABILITY; INTRAPERITONEAL FAT; LIVER HISTOLOGY; MALE; MOUSE; MUSCLE CELL; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SARCOPENIA; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WESTERN DIET; ANIMAL; C57BL MOUSE; DISEASE MODEL; INTRAABDOMINAL FAT; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE CELL;

ANIMALS; DIET, WESTERN; DISEASE MODELS, ANIMAL; INSULIN-LIKE GROWTH FACTOR I; INTRA-ABDOMINAL FAT; LIVER; MALE; MICE; MICE, INBRED C57BL; MUSCLE FIBERS, SKELETAL; MUSCLE STRENGTH; MUSCLE, SKELETAL; MYOSIN HEAVY CHAINS; NON-ALCOHOLIC FATTY LIVER DISEASE; SARCOPENIA; TRIGLYCERIDES; WEIGHT GAIN;

EID: 84984596140     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4285-0     Document Type: Article

References (42)

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global Epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016;64:73–84.
2. Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:221–235.
3. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.
4. Hong HC, Hwang SY, Choi HY, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology. 2014;59:1772–1778.
5. Issa D, Alkhouri N, Tsien C, et al. Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. Hepatology. 2014;60:428–429.
6. Lee YH, Kim SU, Song K, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008–2011). Hepatology. 2016;63:776–786.
7. Merli M, Dasarathy S. Sarcopenia in non-alcoholic fatty liver disease: targeting the real culprit? J Hepatol. 2015;63:309–311.
8. Carnagarin R, Dharmarajan AM, Dass CR. Molecular aspects of glucose homeostasis in skeletal muscle—a focus on the molecular mechanisms of insulin resistance. Mol Cell Endocrinol. 2015;417:52–62.
9. Dongiovanni P, Rametta R, Meroni M, Valenti L. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development—a potential therapeutic target? Expert Rev Gastroenterol Hepatol. 2016;10:229–242.
10. Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. Plos One. 2010;5:e10805.
11. Poggiogalle E, Lubrano C, Gnessi L, Mariani S, Lenzi A, Donini LM. Fatty liver index associates with relative sarcopenia and GH/IGF-1 status in obese subjects. PloS One. 2016;11:e0145811.
12. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295:G987–G995.
13. Ibanez P, Solis N, Pizarro M, et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22:846–851.
14. Morales MG, Olguin H, Di Capua G, Brandan E, Simon F, Cabello-Verrugio C. Endotoxin-induced skeletal muscle wasting is prevented by angiotensin-(1-7) through a p38 MAPK-dependent mechanism. Clin Sci. 2015;129:461–476.
15. Morales MG, Abrigo J, Acuna MJ, et al. Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy via the Mas receptor. Dis Models Mech. 2016;9:441–449.
16. Gregorevic P, Plant DR, Leeding KS, Bach LA, Lynch GS. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am J Pathol. 2002;161:2263–2272.
17. Barton ER, Morris L, Kawana M, Bish LT, Toursel T. Systemic administration of l-arginine benefits mdx skeletal muscle function. Muscle Nerve. 2005;32:751–760.
18. Bogdanovich S, McNally EM, Khurana TS. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve. 2008;37:308–316.
19. Morales MG, Cabello-Verrugio C, Santander C, Cabrera D, Goldschmeding R, Brandan E. CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy. J Pathol. 2011;225:490–501.
20. Morales MG, Gutierrez J, Cabello-Verrugio C, et al. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy. Human Mol Genet. 2013;22:4938–4951.
21. Briguet A, Courdier-Fruh I, Foster M, Meier T, Magyar JP. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromusc Disord NMD. 2004;14:675–682.
22. Carr TP, Andresen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem. 1993;26:39–42.
23. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
24. Morales MG, Abrigo J, Acuna MJ, et al. Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor. Mas Dis Models Mech. 2016;9:441–449.
25. Dasarathy S. Cause and management of muscle wasting in chronic liver disease. Curr Opin Gastroenterol. 2016;32:159–165.
26. Sakuma K, Yamaguchi A. Sarcopenic obesity and endocrinal adaptation with age. Int J Endocrinol. 2013;2013:204164.
27. Cuthbertson DJ, Bell JA, Ng SY, Kemp GJ, Kivimaki M, Hamer M. Dynapenic obesity and the risk of incident Type 2 diabetes: the English Longitudinal Study of Ageing. Diabet Med. 2015;33:1052–1059.
28. Karelis AD, Tousignant B, Nantel J, et al. Association of insulin sensitivity and muscle strength in overweight and obese sedentary postmenopausal women. Appl Physiol Nutr Metab. 2007;32:297–301.
29. Camporez JP, Petersen MC, Abudukadier A, et al. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice. Proc Natl Acad Sci USA. 2016;113:2212–2217.
30. Dasarathy S. Is the adiponectin-AMPK-mitochondrial axis involved in progression of nonalcoholic fatty liver disease? Hepatology. 2014;60:22–25.
31. Fusco A, Miele L, D’Uonnolo A, et al. Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol. 2012;77:531–536.
32. Mallea-Gil MS, Ballarino MC, Spiraquis A, et al. IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome. Acta Gastroenterol Latinoam. 2012;42:20–26.
33. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008;154:557–568.
34. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006;119:526-e9.
35. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol Ser A Biol Sci Med Sci. 2002;57:M326–M332.
36. Dasarathy S. Cause and management of muscle wasting in chronic liver disease. Curr Opin Gastroenterol. 2016;32:159–165.
37. Wree A, Schlattjan M, Bechmann LP, et al. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism. 2014;63:1542–1552.
38. Gill MS, Toogood AA, O’Neill PA, et al. Relationship between growth hormone (GH) status, serum leptin and body composition in healthy and GH deficient elderly subjects. Clin Endocrinol. 1997;47:161–167.
39. Morioka T, Mori K, Motoyama K, Emoto M. Ectopic fat accumulation and glucose homeostasis: role of leptin in glucose and lipid metabolism and mass maintenance in skeletal muscle. In: Inaba M, ed. Musculoskeletal Disease Associated with Diabetes Mellitus. New York: Springer; 2016:201–215.
40. Casanueva FF, Dieguez C. Interaction between body composition, leptin and growth hormone status. Bailliere’s Clin Endocrinol Metab. 1998;12:297–314.
41. Dieguez C, Carro E, Seoane LM, et al. Regulation of somatotroph cell function by the adipose tissue. Int J Obes Relat Metab Disord. 2000;24:S100–S103.
42. Antonione R, Caliandro E, Zorat F, Guarnieri G, Heer M, Biolo G. Whey protein ingestion enhances postprandial anabolism during short-term bed rest in young men. J Nutr. 2008;138:2212–2216.